ABL Bio secures FDA Fast Track for gastric cancer therapy

ABL Bio said Wednesday that the US Food and Drug Administration granted Fast Track designation to Givastomig (ABL111), its gastric cancer treatment candidate being jointly developed with NovaRock Biotherapeutics. The FDA's Fast Track program is designed to speed up the development and review of drugs that treat serious conditions and address unmet medical needs. Givastomig is a bispecific antibody that targets Claudin 18.2, a protein commonly overexpressed in gastric and pancreatic cancers, and

By The Korea Herald